CanSino: Net profit of 27.87 million yuan in 2025, turning losses into profits year-on-year

People’s Finance News, March 30, 2025: CanSino (688185) disclosed its annual report on March 30. In 2025, it achieved operating revenue of 1.068 billion yuan, up 26.18% year over year; net profit attributable to shareholders was 27.87 million yuan, compared with a loss of 379 million yuan in the same period last year, turning from loss to profit year over year; and basic earnings per share were 0.11 yuan. During the reporting period, the company’s first quadrivalent meningococcal conjugate vaccine in China, Menhain® , saw its revenue continue to grow steadily. Meanwhile, the Group continued to advance cost reduction and efficiency improvement, with all expense expenditures effectively controlled; sales and production coordination was further optimized, and the gross margin also improved. The Group also received support from government special grants and international special R&D funding, and recorded related non-recurring gains during the reporting period; it successfully achieved positive net profit attributable to owners of the parent company during the reporting period.